Assessing the Impact of Pegylated-Interferon/Ribavirin Therapy Duration Versus Viral Response on Health-Related Quality of Life (Qol) Outcomes In Chronic Hepatitis C Virus (Hcv) Patients, Using Multivariate Mixed-Effects Modeling
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1411
https://www.valueinhealthjournal.com/article/S1098-3015(15)01468-0/fulltext
Title :
Assessing the Impact of Pegylated-Interferon/Ribavirin Therapy Duration Versus Viral Response on Health-Related Quality of Life (Qol) Outcomes In Chronic Hepatitis C Virus (Hcv) Patients, Using Multivariate Mixed-Effects Modeling
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01468-0&doi=10.1016/j.jval.2015.03.1411
First page :
A242
Section Title :
Infection
Open access? :
No
Section Order :
879